Is the product safe for consumption?

Yes, it passes strict tests for heavy metals, pesticides, and microbiological safety.

Where is the nearest shipping port?

The nearest port is Shanghai Port, with options for sea, air, or express shipping.

SOST Eurycomanone 3% Tongkat Ali Root Powder 200:1 for Men

Name: SOST Eurycomanone 3% Tongkat Ali Root Powder 200:1 for Men
Brand: Xi an Sost Biotech Co., Ltd.
SKU: 1911701325

Shaanxi, ChinaXi an Sost Biotech Co., Ltd.

US$89.00-279.00

2 kg

Product profile

Customization

Available

Certification

ISO, EU Organic/Kosher/Halal

Assay Method

TLC

Model NO.

Tongkat Ali Root Powder 200:1 for Men

Application Form

Powder

Application

Food, Health Care Products, Medicine

State

Powder

Extract Source

Root

Transport Package

Aluminum Foil Bag/Drum

Trademark

SOST

Origin

China

Production Capacity

50000kgs/Month

Key features

High Potency Extract: 200:1 concentration with 3% Eurycomanone content for maximum efficacy.

Comprehensive Certifications: ISO, EU Organic, Kosher, and Halal certified for global market compliance.

Strict Quality Control: Passed heavy metal, pesticide, and microbiological safety tests with low ash content.

Versatile Applications: Suitable for pharmaceuticals, health food supplements, and medicine formulations.

Customization Services: OEM and ODM services available for tailored product solutions.

Fast Lead Time: Peak and off-peak season production completed within 15 working days.

Global Logistics Options: Flexible shipping via Express, Air, or Sea with USA warehouse availability.

Company profile

Xi an Sost Biotech Co., Ltd.

Shaanxi, China

CertifiedBusiness Type: Manufacturer/Factory CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2012-11-01 CertifiedNearest Port: Shanghai PortAverage Response Time: ≤2.74h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryXi'an Sost Biotech Co., Ltd. is identified as a China-based manufacturer and trading company focused on herbal extracts, Chinese medicine raw materials, cosmetic ingredients, healthcare ingredients, food additives, and dietary supplement ingredients. Evidence indicates established production, R&D, sales, purchasing, and quality-control functions, with stated GMP-oriented operations, ISO 9001:2015 certification, multiple production bases, and broad export coverage. However, the records contain conflicting production information: one slice reports three production bases and eight lines, while another reports a 2,990 m² plant and two production lines. The supplier states that it provides pre- and after-sales service and accepts several trade and payment terms, but detailed service performance, customization results, customer references, and financial strength are not sufficiently documented. Monetary figures are omitted.

Supplier typeThe supplier is explicitly classified as a manufacturer and limited company, while another record identifies its business nature as a trading company. Its stated activities include R&D, production, sales, and service of herbal extracts and natural raw materials, so it appears to combine manufacturing and trading functions.

CertificationsThe supplier reports ISO 9001:2015 certification and states that production follows national GMP standards, with GMP-standard factories and 100,000-level clean workshops. ISO certification is explicit; the GMP statements are operational claims rather than a separately named certificate.

After-Sales capabilityThe company explicitly emphasizes before-sales and after-sales service, states that it continuously improves service, and describes service as part of its business operations. However, no evidence gives measurable after-sales performance, service staffing, response times, or documented customer outcomes.

R&D capabilityThe supplier reports an R&D department, research and development of high-purity natural products, biological engineering and natural extraction technology, and an innovation-oriented approach. Nevertheless, only two years of R&D engineer experience are reported, and there is no evidence of patents, new-product records, or quantified R&D achievements.

Production capacityProduction capability is supported by a stated manufacturing plant, natural-extract production activities, GMP-oriented facilities, clean workshops, and product lines covering food, healthcare, cosmetics, and pharmaceutical intermediates. The data are inconsistent: one record states three production bases and eight lines, while another reports a 2,990 m² plant and two lines; quality-control staffing is also reported as fewer than five employees.